

## Institutional Biosafety Committee - Regular Meeting

Thursday, July 02, 2026

Zoom

### Meeting Minutes

|                                    |                                                                                                                                            |
|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| VOTING MEMBERS PRESENT:            | S. Apewokin, K. Burns, J. Corcoran, G. Dean, D. Elsaesser, M. Espinola, S. Kasper, R. Larson, E. Otten, T. Rausch, F. Schaefer, E. Serafin |
| VOTING MEMBERS NOT PRESENT:        | G. Babcock                                                                                                                                 |
| AD HOC MEMBERS/CONSULTANTS/GUESTS: | T. Gulley                                                                                                                                  |
| IBC STAFF:                         | D. Healy, B. Kesavalu                                                                                                                      |

K. Burns convened the meeting at 12:00 p.m.

- I. **Conflicts of Interest** - No conflicts were identified.
- II. **Minutes** - Minutes from the previous IBC meeting (06/04/26) was approved (11: YES/0: NO/1: Abstained)
- III. **Old Business** - No old business to discuss
- IV. **New Business**

#### A. Primary Protocols (1 protocol)

| IBC Protocol Number | PI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Type of Submission | Biosafety Level | IBC Items                                                                                                    |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------|--------------------------------------------------------------------------------------------------------------|
| 1. 24-02-08-01      | Borchers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Amendment          | BSL2            | <b><i>in vitro</i></b> : HDM (blood, serum, plasma)<br><b>AMENDMENT: <i>in vitro</i></b> : Adenoviral vector |
| IBC Requests:       | <p><b><u>Main Form – General Safety:</u></b></p> <ol style="list-style-type: none"> <li><b>Section I. B</b> - if Secondary Contact doesn't have an office nor a lab phone, enter "N/A";</li> <li><b>Section II. B</b> - Expand description to indicate the relevance of the genes that are manipulated by Cre Recombinase and also describe the downstream assays involving virally transduced cells;</li> <li><b>Section III. A – Pipet</b> - In addition to filtered tips there are safety measures that need to be followed while pipetting. For information on aerosol mitigation procedures, consult the eManual (link provided on the top of this section);</li> <li><b>Section III. A – Tissue Grinder</b> – Correct spelling errors: “the is”, “sus[pensions]”;</li> <li><b>Section III. C</b> - In "Additional Information", explain when, face (surgical) masks will be used;</li> <li><b>Section VIII</b> – Include lentivirus in case that is still in storage and not totally discarded.</li> </ol> <p><b><u>Form A – Recombinant or Synthetic Nucleic Acid:</u></b></p> <ol style="list-style-type: none"> <li><b>Section I</b> - "Gene Source" should read "virus". Also, check "Additional Information" and indicate which host genes are the target for Cre Recombinase;</li> <li><b>Section II. A</b> - In a previous communication, it was stated that vectors are obtained from ADDGene. Revise section if necessary;</li> <li><b>Section II. B - #1</b> - Check YES for "Additional Information" and describe the use of adenoviral vector and downstream experiments with virally transduced cells.</li> </ol> <p><b><u>Form C – Human and NHP Derived Materials:</u></b></p> <ol style="list-style-type: none"> <li><b>Section II. A - Second Paragraph</b> - Do you also use the CCHMC Flow Core to sort human viable cells? If so, include this information in this section.</li> </ol> |                    |                 |                                                                                                              |

|                                     |                                                        |              |                     |                     |
|-------------------------------------|--------------------------------------------------------|--------------|---------------------|---------------------|
| <b>Motion</b>                       | Approve upon modifications addressing outlined issues. |              |                     |                     |
| <b>Voting Result &amp; Dual Use</b> | <b>YES: 12</b>                                         | <b>NO: 0</b> | <b>Abstained: 0</b> | <b>Dual Use? No</b> |

B. Secondary Protocols (3 protocols)

| IBC Protocol Number                 | PI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Type of Submission | Biosafety Level     | IBC Items                                                                                                                                                |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. 26-06-10-01                      | Qi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Renewal            | BSL2                | <i>in vitro</i> : <i>Escherichia coli</i> (BL21 - RG1)<br><i>in vitro</i> and <i>in vivo</i> : HDM (cancer and macrophage cell lines)<br>- Core facility |
| <b>IBC Requests:</b>                | <p><b><u>Form A – Recombinant or Synthetic Nucleic Acid:</u></b></p> <ol style="list-style-type: none"> <li><b>Section II. B</b> - Include Cas 9 gene in this section;</li> <li><b>Section II. B</b> - Form B mentions bacterial expression of recombinant Saposin C. This gene (and any other genes) needs to be included in this section;</li> </ol> <p><b><u>Form C – Human and NHP Derived Materials:</u></b></p> <ol style="list-style-type: none"> <li><b>Section I - Table</b> - Provide examples of source for established and primary cells (suppliers? collaborators?).</li> </ol> <p><b><u>Form D – Biohazard in Animals:</u></b></p> <ol style="list-style-type: none"> <li><b>Section I</b> - Provide your current IACUC protocol number.</li> </ol> |                    |                     |                                                                                                                                                          |
| <b>Motion</b>                       | Approve upon modifications addressing outlined issues.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                    |                     |                                                                                                                                                          |
| <b>Voting Result &amp; Dual Use</b> | <b>YES: 12</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <b>NO: 0</b>       | <b>Abstained: 0</b> | <b>Dual Use? No</b>                                                                                                                                      |

| IBC Protocol Number  | PI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Type of Submission | Biosafety Level | IBC Items                                                                                       |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------|-------------------------------------------------------------------------------------------------|
| 2. 26-06-11-01       | Seegar                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Renewal            | BSL2            | <i>in vitro</i> : Baculoviral vector, <i>Escherichia coli</i> (BL21 - RG1) and HDM (cell lines) |
| <b>IBC Requests:</b> | <p><b><u>Main Form – General Safety:</u></b></p> <ol style="list-style-type: none"> <li><b>Section I. B</b> - If Secondary Contact does not have an office number, enter "N/A";</li> <li><b>Section II. E</b> - In Form C, there is a statement that HEK cells are used for large scale production of protein. Does that involve any single vessel of more than 10 L? If so, modify section accordingly;</li> <li><b>Section II. C - Additional Information - 1st paragraph</b> - Replace "encouraged" with "required" to use appropriate PPE;</li> <li><b>Main Form - Section III. A. - Centrifuge</b> - Change the last line to read as follows: "Tubes will not be overfilled and will be balanced."</li> </ol> <p><b><u>Form A – Recombinant or Synthetic Nucleic Acid:</u></b></p> <ol style="list-style-type: none"> <li><b>Section II. B - Systems #1 and #2</b> - Verify "human tropism";</li> <li><b>Section II. B - System #2</b> - Check "<i>in vitro</i>" and add mVenus to expressed genes list;</li> <li><b>Section II. B - System #2</b> - Are the genes expressed independently of each other? Respond in the "Additional information" section if not.</li> </ol> |                    |                 |                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                |              |                     |                     |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------|---------------------|
|                                     | <b>Form B – Microbial/Infectious Agents</b><br>8. <b>Agent#1 and Agent#2 - Genetically Modified</b> - Include a comma between different genes unless this is one gene. Also, for “Source” does the “Thermo” mean “Thermo Fisher Scientific”? Revise section accordingly<br><b>Form C – Human and NHP Derived Materials:</b><br>9. <b>Section I</b> (Table) - Provide the source of the established cell lines. |              |                     |                     |
| <b>Motion</b>                       | Approve upon modifications addressing outlined issues.                                                                                                                                                                                                                                                                                                                                                         |              |                     |                     |
| <b>Voting Result &amp; Dual Use</b> | <b>YES: 12</b>                                                                                                                                                                                                                                                                                                                                                                                                 | <b>NO: 0</b> | <b>Abstained: 0</b> | <b>Dual Use? No</b> |

| IBC Protocol Number                 | PI                                                                                                                                                                                                                                                                                                               | Type of Submission | Biosafety Level     | IBC Items                   |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------|-----------------------------|
| 3. 26-06-11-02                      | Kruyer                                                                                                                                                                                                                                                                                                           | Renewal            | BSL1                | <u>in vivo</u> : AAV vector |
| <b>IBC Requests:</b>                | <b>Main Form – General Safety:</b><br>1. <b>Section III. A</b> - Will you use vortex to mix viral vector suspensions? If so, select “vortex” and include mitigation strategies;<br>2. <b>Section III. C</b> - In "Additional Information", explain when face (surgical) masks and safety goggles are being used. |                    |                     |                             |
| <b>Motion</b>                       | Approve upon modifications addressing outlined issues.                                                                                                                                                                                                                                                           |                    |                     |                             |
| <b>Voting Result &amp; Dual Use</b> | <b>YES: 12</b>                                                                                                                                                                                                                                                                                                   | <b>NO: 0</b>       | <b>Abstained: 0</b> | <b>Dual Use? No</b>         |

## II. Protocol Updates - May 28<sup>th</sup> to June 26<sup>th</sup> (31 protocols)

- IBC# 26-05-06-01 - PI: Phoenix - Personnel
- IBC# 25-03-19-02 - PI: Plas - Form A and Form C
- IBC# 24-06-18-01 - PI: Nayak - personnel
- IBC# 24-02-13-01 - PI: Ionascu - Personnel
- IBC# 24-09-18-01 - PI: Dodson - Personnel
- IBC# 24-03-08-03 - PI: Esfandiari - Personnel
- IBC# 23-09-27-01 - PI: Steckl - Personnel
- IBC# 23-09-14-01 - PI: Schutte - Personnel
- IBC# 25-12-12-02 - PI: Kotagiri - Personnel
- IBC# 26-04-06-01 - PI: Zhang P - Personnel
- IBC# 24-02-23-01 - PI: Apewokin - Personnel
- IBC# 24-08-21-01 - PI: Yan - Amendment in vivo: Human cells (HepG2)
- IBC# 25-12-12-02 - PI: Kotagiri - Amendment in vitro and in vivo: *Bifidobacterium longum*, *Lactococcus lactis*, human primary T cells
- IBC# 24-01-24-01 - PI: Garrett - Personnel
- IBC# 24-04-04-01 - PI: Heikenfeld - Personnel
- IBC# 24-06-18-02 - PI: Hertlein - Personnel
- IBC# 24-01-02-01 - PI: Waltz - Personnel
- IBC# 24-06-22-01 - PI: Hoilett - Personnel
- IBC# 25-10-21-02 - PI: Strobbia - Amendment: Add Cucumber Mosaic Virus; Remove Soy Mosaic Virus
- IBC# 26-01-13-01 - PI: Dion - personnel
- IBC# 24-12-09-01 - PI: Deepe - Personnel

22. IBC# 23-12-19-01 - PI: Huang W - Personnel
23. IBC# 25-01-07-02 - PI: Wang YG - Personnel
24. IBC# 25-11-03-01 - PI: Miller-Handley - Personnel
25. IBC# 24-01-18-01 - PI: Ikegami - Location (BSC)
26. IBC#23-08-04-23 - PI: Wang X - Personnel, secondary contact
27. IBC# 25-07-07-01 - PI: Hudock - Personnel
28. IBC# 25-02-14-01 - PI: Liu - Personnel
29. IBC# 23-12-19-01 - PI: Huang W - Personnel
30. IBC# 24-03-11-01 - PI: Burns - Personnel
31. IBC# 25-05-06-01 - PI: Madala - Personnel

## VI. Reports

- A. IBC/BSOf (M. Espinola)
  - NIH/OSP Reportable Incident: Lack of IBC approval
    - During an annual laboratory inspection, it was discovered that a research group had previously used adenoviral vector without obtaining IBC approval, a finding that is reportable to NIH/OSP.
    - An initial report was sent on June 16, 2026 to NIH/OSP and a formal report will be submitted when the protocol amendment is approved (within 30 days of first report).
    - BSOf is creating a compliance form for all PIs to verify all NIH-reportable items.
  - FY26: IBC Active Protocols & Approvals- The metrics of active protocols and approvals for the FY26 was presented.

## VII. Educational Materials/Updates

- A. **Monkeypox Smuggling**
  - **NIH scientists charged with smuggling viruses into U.S.** Science, June 2026
  - **2 researchers charged with smuggling mpox into the US** POLITICO, June 2026
- B. **Can LLM agents select and engage with biological tools** RAND Research Report, 2026

K. Burns adjourned the meeting at 12:22 p.m.

